Real-World Assessment of Clinical Outcomes Among First-Line Sunitinib Patients with Clear Cell Metastatic Renal Cell Carcinoma (mRCC) by the International mRCC Database Consortium Risk Group.
International Metastatic Renal Cell Carcinoma Database Consortium
Metastatic renal cell carcinoma
Overall survival
Real-world clinical outcome
Sunitinib
Journal
The oncologist
ISSN: 1549-490X
Titre abrégé: Oncologist
Pays: England
ID NLM: 9607837
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
received:
07
08
2019
accepted:
19
12
2019
pubmed:
24
1
2020
medline:
22
6
2021
entrez:
24
1
2020
Statut:
ppublish
Résumé
International Metastatic Renal Cell Carcinoma (mRCC) Database Consortium (IMDC) risk groups are important when considering therapeutic options for first-line treatment. Adult patients with clear cell mRCC initiating first-line sunitinib between 2010 and 2018 were included in this retrospective database study. Median time to treatment discontinuation (TTD) and overall survival (OS) were estimated using Kaplan-Meier analysis. Outcomes were stratified by IMDC risk groups and evaluated for those in the combined intermediate and poor risk group and separately for those in the intermediate risk group with one versus two risk factors. Among 1,769 patients treated with first-line sunitinib, 318 (18%) had favorable, 1,031 (58%) had intermediate, and 420 (24%) had poor IMDC risk. Across the three risk groups, patients had similar age, gender, and sunitinib initiation year. Median TTD was 15.0, 8.5, and 4.2 months in the favorable, intermediate, and poor risk groups, respectively, and 7.1 months in the combined intermediate and poor risk group. Median OS was 52.1, 31.5, and 9.8 months in the favorable, intermediate, and poor risk groups, respectively, and 23.2 months in the combined intermediate and poor risk group. Median OS (35.1 vs. 21.9 months) and TTD (10.3 vs. 6.6 months) were significantly different between intermediate risk patients with one versus two risk factors. This real-world study found a median OS of 52 months for patients with favorable IMDC risk treated with first-line sunitinib, setting a new benchmark on clinical outcomes of clear cell mRCC. Analysis of intermediate risk group by one or two risk factors demonstrated distinct clinical outcomes. This analysis offers a contemporary benchmark for overall survival (median, 52.1 months; 95% confidence interval, 43.4-61.2) among patients with clear cell metastatic renal cell carcinoma who were treated with sunitinib as first-line therapy in a real-world setting and classified as favorable risk according to International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk group classification. This study demonstrates that clinical outcomes differ between IMDC risk groups as well as within the intermediate risk group based on the number of risk factors, thus warranting further consideration of risk group when counseling patients about therapeutic options and designing clinical trials.
Sections du résumé
BACKGROUND
International Metastatic Renal Cell Carcinoma (mRCC) Database Consortium (IMDC) risk groups are important when considering therapeutic options for first-line treatment.
MATERIALS AND METHODS
Adult patients with clear cell mRCC initiating first-line sunitinib between 2010 and 2018 were included in this retrospective database study. Median time to treatment discontinuation (TTD) and overall survival (OS) were estimated using Kaplan-Meier analysis. Outcomes were stratified by IMDC risk groups and evaluated for those in the combined intermediate and poor risk group and separately for those in the intermediate risk group with one versus two risk factors.
RESULTS
Among 1,769 patients treated with first-line sunitinib, 318 (18%) had favorable, 1,031 (58%) had intermediate, and 420 (24%) had poor IMDC risk. Across the three risk groups, patients had similar age, gender, and sunitinib initiation year. Median TTD was 15.0, 8.5, and 4.2 months in the favorable, intermediate, and poor risk groups, respectively, and 7.1 months in the combined intermediate and poor risk group. Median OS was 52.1, 31.5, and 9.8 months in the favorable, intermediate, and poor risk groups, respectively, and 23.2 months in the combined intermediate and poor risk group. Median OS (35.1 vs. 21.9 months) and TTD (10.3 vs. 6.6 months) were significantly different between intermediate risk patients with one versus two risk factors.
CONCLUSION
This real-world study found a median OS of 52 months for patients with favorable IMDC risk treated with first-line sunitinib, setting a new benchmark on clinical outcomes of clear cell mRCC. Analysis of intermediate risk group by one or two risk factors demonstrated distinct clinical outcomes.
IMPLICATIONS FOR PRACTICE
This analysis offers a contemporary benchmark for overall survival (median, 52.1 months; 95% confidence interval, 43.4-61.2) among patients with clear cell metastatic renal cell carcinoma who were treated with sunitinib as first-line therapy in a real-world setting and classified as favorable risk according to International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk group classification. This study demonstrates that clinical outcomes differ between IMDC risk groups as well as within the intermediate risk group based on the number of risk factors, thus warranting further consideration of risk group when counseling patients about therapeutic options and designing clinical trials.
Identifiants
pubmed: 31971318
doi: 10.1634/theoncologist.2019-0605
pmc: PMC7216460
doi:
Substances chimiques
Sunitinib
V99T50803M
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
422-430Informations de copyright
© AlphaMed Press 2020.
Références
Oncologist. 2019 Mar;24(3):366-371
pubmed: 30710066
J Clin Oncol. 2017 Feb 20;35(6):591-597
pubmed: 28199818
Clin Genitourin Cancer. 2018 Aug;16(4):298-304
pubmed: 29853320
J Clin Oncol. 2009 Dec 1;27(34):5794-9
pubmed: 19826129
N Engl J Med. 2019 Mar 21;380(12):1116-1127
pubmed: 30779529
N Engl J Med. 2018 Apr 05;378(14):1277-1290
pubmed: 29562145
Lancet Oncol. 2013 Feb;14(2):141-8
pubmed: 23312463
Oncologist. 2019 Mar;24(3):338-348
pubmed: 30158285
J Clin Oncol. 2009 Aug 1;27(22):3584-90
pubmed: 19487381
Cancer. 2013 Aug 15;119(16):2999-3006
pubmed: 23696129
Eur Urol. 2017 Feb;71(2):204-209
pubmed: 27318422
N Engl J Med. 2019 Mar 21;380(12):1103-1115
pubmed: 30779531
Cancer. 2017 Jun 1;123(11):1904-1911
pubmed: 28241095
Eur Urol Focus. 2016 Aug;2(3):303-309
pubmed: 28723377
Expert Opin Biol Ther. 2018 Sep;18(9):947-957
pubmed: 30124333